Short Interest in Replimune Group Inc (NASDAQ:REPL) Increases By 14.2%

Replimune Group Inc (NASDAQ:REPL) saw a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 635,300 shares, an increase of 14.2% from the September 30th total of 556,300 shares. Currently, 8.0% of the company’s shares are sold short. Based on an average daily volume of 59,000 shares, the short-interest ratio is presently 10.8 days.

A number of research firms recently commented on REPL. Chardan Capital reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Replimune Group in a research note on Thursday, October 24th. Roth Capital boosted their price target on Replimune Group from $20.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, November 11th. HC Wainwright reissued a “buy” rating and issued a $26.00 price target on shares of Replimune Group in a research note on Monday, September 30th. Zacks Investment Research lowered Replimune Group from a “buy” rating to a “hold” rating in a research note on Friday. Finally, ValuEngine raised Replimune Group from a “sell” rating to a “hold” rating in a research note on Monday, November 4th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $25.17.

In related news, COO Colin Love sold 11,250 shares of Replimune Group stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $17.05, for a total value of $191,812.50. Also, CEO Robert Coffin sold 24,250 shares of Replimune Group stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $17.05, for a total value of $413,462.50. Over the last 90 days, insiders have sold 200,000 shares of company stock worth $3,395,500. Company insiders own 63.18% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of REPL. Emerald Mutual Fund Advisers Trust lifted its holdings in Replimune Group by 0.5% during the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 711,770 shares of the company’s stock worth $10,435,000 after purchasing an additional 3,650 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Replimune Group by 211.3% during the 2nd quarter. Wells Fargo & Company MN now owns 23,090 shares of the company’s stock worth $338,000 after purchasing an additional 15,672 shares in the last quarter. Northern Trust Corp lifted its holdings in Replimune Group by 1.2% during the 2nd quarter. Northern Trust Corp now owns 123,931 shares of the company’s stock worth $1,817,000 after purchasing an additional 1,437 shares in the last quarter. Foresite Capital Management III LLC lifted its holdings in Replimune Group by 4.0% during the 2nd quarter. Foresite Capital Management III LLC now owns 779,656 shares of the company’s stock worth $11,430,000 after purchasing an additional 30,002 shares in the last quarter. Finally, BlackRock Inc. lifted its holdings in Replimune Group by 8.2% during the 2nd quarter. BlackRock Inc. now owns 1,015,225 shares of the company’s stock worth $14,883,000 after purchasing an additional 76,540 shares in the last quarter. 60.92% of the stock is currently owned by hedge funds and other institutional investors.

REPL traded down $1.44 during trading on Friday, hitting $12.20. The company’s stock had a trading volume of 819,800 shares, compared to its average volume of 194,376. Replimune Group has a twelve month low of $8.88 and a twelve month high of $18.25. The company has a quick ratio of 9.79, a current ratio of 9.85 and a debt-to-equity ratio of 0.16. The stock’s fifty day moving average price is $14.49 and its 200-day moving average price is $13.44. The firm has a market capitalization of $436.60 million, a P/E ratio of -9.17 and a beta of 3.30.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Monday, November 11th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). Equities research analysts expect that Replimune Group will post -1.4 EPS for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Featured Story: What are the benefits of investing in REITs?

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.